FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

FDA Approves Luxturna for Rare Vision Loss

FDA approves Spark Therapeutics Luxturna for treating patients with a form of retinal dystrophy.

Human Drugs

FDA Risk-Based Enforcement for Homeopathic Drugs

FDA says it will take a new risk-based enforcement approach to homeopathic drugs that are marketed for serious illnesses or dont have demonstrated cli...

Human Drugs

Senators Question Drug Import Enforcement

Senators Grassley and Klobuchar ask FDA if the non-enforcement policy for some drug importation from Canada has changed.

Medical Devices

FDA Clears GammaPod Breast Cancer Treatment

FDA clears Xcision Medical Systems GammaPod breast cancer radiation treatment.

Medical Devices

FDA Permits Marketing of Dermapace Foot Ulcer Device

FDA allows marketing of Sanuwaves Dermapace System to treat diabetic foot ulcers in adult patients with pulses of energy to mechanically stimulate the...

Human Drugs

CDER Approvals Double to 46 Innovative Products

CDER innovative drug approvals sharply rebound in 2017 more than doubling the 22 products approved in 2016, which was a significant down year for app...

Human Drugs

FDA Issues 2 Drug Communication Guidances

FDA releases two guidances on communications with drug sponsors.

Human Drugs

3rd Circuit Expanded Antitrust Law: WLF

Washington Legal Foundation asks the Supreme Court to hear Pfizers appeal of a 3rd Circuit Appeals Court decision on a patent settlement between Pfize...

Human Drugs

Some OTC Antiseptic Ingredients Not GRASE

FDA issues a final rule designating 24 ingredients in OTC antiseptic products intended for use by healthcare professionals as not generally recognized...

Human Drugs

Some Tasigna Patients May be Able to Stop Treatment: FDA

FDA says some patients may discontinue Tasigna after taking it for three years or more and remain in remission for up to 96 weeks.